CD274 and neoplasm: KEYNOTE-042 clinical trials demonstrated that first-line pembrolizumab monotherapy harbored longer progression-free survival (PFS) than chemotherapy for patients with untreated metastatic NSCLC and PD-L1 tumor proportion scores ≥50%, ≥20%, and ≥1% (17).